NCT05395052 2023-09-21
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
Fate Therapeutics
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Royal Marsden NHS Foundation Trust
Odense University Hospital
Eli Lilly and Company